AMRX

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.06
Percentage change -0.72	%

Peers: JNJ PFE NVS TAK TEVA PRGO FMS RDY SNN

| Held by: VTI IWM VB VBR VXF IWO DFAS PJP SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	54.15%	Shs Outstand	313.38M	Perf Week	-1.07%
Market Cap	2.61B	Forward P/E	10.07	EPS next Y	0.83	Insider Trans	-3.36%	Shs Float	143.72M	Perf Month	6.66%
Enterprise Value	5.20B	PEG	-	EPS next Q	0.17	Inst Own	39.71%	Short Float	4.56%	Perf Quarter	12.11%
Income	-13.05M	P/S	0.92	EPS this Y	21.55%	Inst Trans	7.69%	Short Ratio	3.59	Perf Half Y	5.84%
Sales	2.83B	P/B	-	EPS next Y	17.38%	ROA	-0.38%	Short Interest	6.55M	Perf YTD	5.18%
Book/sh	-0.42	P/C	39.70	EPS next 5Y	20.97%	ROE	-155.38%	52W High	9.48 -12.08%	Perf Year	22.32%
Cash/sh	0.21	P/FCF	10.77	EPS past 3/5Y	- 32.70%	ROIC	-0.62%	52W Low	6.50 28.15%	Perf 3Y	158.70%
Dividend Est.	-	EV/EBITDA	8.58	Sales past 3/5Y	10.10% 11.43%	Gross Margin	36.69%	Volatility	2.41% 2.78%	Perf 5Y	77.99%
Dividend TTM	-	EV/Sales	1.84	EPS Y/Y TTM	92.50%	Oper. Margin	12.89%	ATR (14)	0.23	Perf 10Y	-82.01%
Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	13.42%	Profit Margin	-0.46%	RSI (14)	60.64	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.40	EPS Q/Q	112.61%	SMA20	2.44%	Beta	1.12	Target Price	11.75
Payout	-	Debt/Eq	-	Sales Q/Q	5.50%	SMA50	7.88%	Rel Volume	0.80	Prev Close	8.39
Employees	8300	LT Debt/Eq	-	Earnings	Aug 05 BMO	SMA200	2.71%	Avg Volume	1.83M	Price	8.33
IPO	Dec 19, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.15% -2.71%	Trades		Volume	1,466,760	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Goldman	Buy	$12
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight	$9 → $12
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral	$9
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$5
Mar-08-21	Upgrade	Goldman	Sell → Buy	$4 → $6.50
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy	$5.50
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight	$4.50 → $6
Jul-27-20	Initiated	Goldman	Sell	$4
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$11 → $5
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11 → $6
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight	$9
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy	$13
Mar-20-19	Initiated	SunTrust	Buy	$16
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$16 → $12
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Jul-11-25 11:27AM	Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension (Insider Monkey)
Jul-09-25 08:00AM	Amneal to Report Second Quarter 2025 Results on August 5, 2025 (GlobeNewswire)
Jul-02-25 10:09PM	Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares (Insider Monkey)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
05:46PM	Loading…
Jun-26-25 05:46PM	5 Revealing Analyst Questions From Amneal's Q1 Earnings Call (StockStory)
Jun-25-25 08:00AM	Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences (GlobeNewswire)
Jun-17-25 10:00AM	Generic Drugmakers Resist Trumps Calls for More U.S. Manufacturing (The Wall Street Journal)
Jun-13-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Jun-12-25 08:00AM	Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension (GlobeNewswire)
Jun-10-25 09:15AM	Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-04-25 09:55AM	Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade (Zacks)
May-29-25 04:05PM	Amneal to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-26-25 12:45PM	3 Reasons Growth Investors Will Love Amneal (AMRX) (Zacks)
May-16-25 09:11AM	AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress (StockStory)
08:00AM	Loading…
May-15-25 08:00AM	Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults (GlobeNewswire)
May-09-25 09:55AM	Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? (Zacks)
May-08-25 12:45PM	Here is Why Growth Investors Should Buy Amneal (AMRX) Now (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? (Zacks)
07:00AM	Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. (GlobeNewswire)
12:35AM	3 Value Stocks in Hot Water (StockStory)
May-07-25 12:31AM	3 Small-Cap Stocks Facing Headwinds (StockStory)
May-03-25 03:03AM	Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-02-25 11:32AM	Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
06:00AM	Amneal Reports First Quarter 2025 Financial Results (Business Wire)
May-01-25 09:23AM	Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 07:18AM	Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings (Zacks)
Apr-29-25 09:06AM	3 Profitable Stocks Skating on Thin Ice (StockStory)
05:05AM	Loading…
Apr-28-25 05:05AM	Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest (StockStory)
Apr-25-25 10:00AM	Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 05:02AM	2 Reasons to Avoid AMRX and 1 Stock to Buy Instead (StockStory)
Apr-15-25 01:44PM	Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Amneal Donates $1.5 Million to Support Patients During Parkinsons Awareness Month (Business Wire)
Apr-08-25 04:05PM	Amneal to Report First Quarter 2025 Results on May 2, 2025 (Business Wire) +6.29%
Apr-07-25 08:00AM	Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Parkinsons Disease (Business Wire)
Apr-03-25 08:00AM	Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinsons Disease Patients in the U.S. (Business Wire)
Apr-01-25 08:00AM	Amneal Launches BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma (Business Wire)
Mar-19-25 03:14PM	Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (SeekingAlpha)
Mar-10-25 04:05PM	Amneal to Participate at Upcoming Investor Conference (Business Wire)
Mar-03-25 04:05PM	Amneals BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA (Business Wire)
Mar-01-25 02:53PM	Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-28-25 06:00AM	Amneal Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-27-25 07:10AM	Amneal Pharmaceuticals Inc (AMRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-25 08:00AM	Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide (Business Wire)
Jan-30-25 06:22AM	7MM PD market to grow by $4.5bn between 2023 and 2033 (Clinical Trials Arena)
Jan-29-25 08:30AM	Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 (Business Wire)
07:25AM	Kashiv Biosciences Phase I trial of KSHB002 injection meets primary endpoints (Clinical Trials Arena)
Jan-23-25 11:47PM	FDA approves Amneal Pharmaceuticals' Alzheimer's and oncology treatments (Pharmaceutical Business Review)
08:00AM	Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin (Business Wire)
Dec-04-24 08:00AM	Amneal to Participate at Upcoming Investor Conferences (Business Wire)
Nov-21-24 04:05PM	Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist (Business Wire)
Nov-09-24 04:01PM	Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-08-24 06:00AM	Amneal Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-07-24 07:04AM	Earnings To Watch: Amneal Pharmaceuticals Inc (AMRX) Reports Q3 2024 Result (GuruFocus.com)
Oct-21-24 08:00AM	Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets (Business Wire)
Oct-09-24 06:10PM	Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-08-24 04:05PM	Amneal to Report Third Quarter 2024 Results on November 8, 2024 (Business Wire)
Oct-01-24 06:00AM	Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases (Business Wire)
Sep-24-24 08:45AM	As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse (GlobeNewswire)
Sep-23-24 08:00AM	Amneal Launches CREXONT (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinsons Disease (Business Wire)
Sep-05-24 04:05PM	Amneal and Shilpa Announce U.S. FDA Approval of BORUZU, the First Ready-to-Use Version of Bortezomib for subcutaneous administration (Business Wire)
Aug-20-24 11:26AM	Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials (Business Wire)
Aug-16-24 11:38PM	Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ... (GuruFocus.com)
Aug-10-24 08:18AM	Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-09-24 10:52AM	AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:05AM	Amneal Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:45PM	Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT (Carbidopa and Levodopa) Extended-Release Capsules (Business Wire) +14.10%
Jul-29-24 04:05PM	Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags (Business Wire)
Jul-11-24 04:05PM	Amneal to Report Second Quarter 2024 Results on August 9, 2024 (Business Wire)
Jul-10-24 07:37AM	Amneal Pharmaceuticals launches ready-to-use injectable FOCINVEZ (Pharmaceutical Business Review)
Jul-09-24 04:05PM	Amneal Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant (Business Wire)
Jul-01-24 08:00AM	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR (Omalizumab) (Business Wire)
08:00AM	Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar (Business Wire)
Jun-28-24 08:00AM	Amneal Releases 2023 Environmental, Social and Governance Report (Business Wire)
Jun-25-24 08:48PM	3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks (InvestorPlace)
Jun-05-24 08:00AM	Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies (Business Wire)
May-23-24 07:03AM	Amneal Pharmaceuticals launches supply of Naloxone HCI Nasal Spray in US (Pharmaceutical Business Review)
May-22-24 04:05PM	Amneal to Participate at Upcoming Investor Conference (Business Wire)
04:05PM	Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California (Business Wire)
May-20-24 07:01PM	Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX) (GuruFocus.com)
May-16-24 06:15AM	Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade (InvestorPlace)
May-04-24 03:05AM	Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-03-24 03:35PM	Bausch Health Companies Inc. (NYSE:BHC) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.86%
10:53AM	AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates (Zacks)
06:00AM	Amneal Reports First Quarter 2024 Financial Results (Business Wire)
Apr-25-24 05:48AM	Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? (Zacks)
Apr-24-24 08:00AM	Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose (Business Wire) +12.04%
Apr-16-24 08:00AM	Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine (Business Wire)
Apr-10-24 08:00AM	Amneal to Report First Quarter 2024 Results on May 3, 2024 (Business Wire)
Mar-28-24 04:05PM	Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 (Business Wire)
Mar-25-24 04:05PM	Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension (Business Wire)
Mar-20-24 06:11AM	Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks)
Mar-04-24 09:07AM	Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 09:30AM	Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates (Zacks)
06:32AM	Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results (GuruFocus.com)

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Gautam	Director	Jun 16 '25	Sale	8.02	94,906	761,146	1,609,144	Jun 18 04:11 PM
Patel Gautam	Director	Jun 10 '25	Sale	8.02	56,426	452,537	1,704,050	Jun 12 04:19 PM
Shah Nikita	Executive Vice President	May 16 '25	Sale	7.58	49,140	372,481	388,929	May 19 04:16 PM
Shah Nikita	Officer	May 16 '25	Proposed Sale	7.50	49,140	368,550		May 16 04:02 PM
Kiely John	Director	May 12 '25	Sale	7.59	50,000	379,500	257,433	May 13 04:42 PM
Kiely John	Director	May 12 '25	Proposed Sale	7.57	50,000	378,500		May 12 04:07 PM
Patel Gautam	Director	May 05 '25	Sale	8.00	4,900	39,200	1,720,218	May 06 04:29 PM
Patel Gautam	Director	May 02 '25	Sale	8.00	3,768	30,144	1,725,118	May 06 04:29 PM
Gautam Patel	Director	May 02 '25	Proposed Sale	7.74	160,000	1,238,400		May 02 04:38 PM
Patel Gautam	Director	Apr 01 '25	Sale	8.30	80,000	664,000	1,728,886	Apr 02 04:12 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Sale	8.35	5,000,000	41,750,000	48,578,209	Mar 17 04:51 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Proposed Sale	8.75	5,000,000	43,750,000		Mar 14 07:32 PM
BOYER ANDREW S	Executive Vice President	Mar 05 '25	Sale	8.89	125,000	1,111,250	290,106	Mar 07 04:18 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 06 '25	Sale	8.73	46,936	409,751	32,606	Mar 07 04:17 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 05 '25	Sale	8.88	43,064	382,408	79,542	Mar 07 04:17 PM
Konidaris Tasos	Executive Vice President & CFO	Mar 05 '25	Sale	8.91	100,000	891,000	621,882	Mar 07 04:17 PM
Alva Emily Peterson	Director	Mar 05 '25	Sale	8.90	80,000	712,000	170,771	Mar 07 04:16 PM
Patel Gautam	Director	Mar 03 '25	Sale	8.90	80,000	712,000	1,808,886	Mar 05 07:12 PM
Alva Emily Peterson	Director	Mar 05 '25	Proposed Sale	8.87	85,000	753,950		Mar 05 05:02 PM
BOYER ANDREW S	Officer	Mar 05 '25	Proposed Sale	8.87	125,000	1,108,750		Mar 05 05:00 PM
Daly Jason B.	Officer	Mar 05 '25	Proposed Sale	8.80	90,000	792,000		Mar 05 04:57 PM
Konidaris Tasos	Officer	Mar 05 '25	Proposed Sale	8.84	100,000	884,000		Mar 05 10:00 AM
Patel Gautam	Director	Feb 03 '25	Sale	8.14	80,000	651,200	1,888,886	Feb 05 04:31 PM
Patel Gautam	Director	Jan 08 '25	Sale	8.01	62,590	501,346	1,968,886	Jan 10 04:25 PM
Patel Gautam	Director	Jan 02 '25	Sale	8.01	17,410	139,454	2,031,476	Jan 06 04:22 PM
Gautam J Patel	Director	Jan 02 '25	Proposed Sale	8.00	320,000	2,560,000		Jan 02 04:48 PM
Kiely John	Director	Nov 22 '24	Option Exercise	4.76	28,506	135,689	284,233	Nov 26 04:41 PM
Kiely John	Director	Nov 22 '24	Sale	8.38	17,058	142,946	267,175	Nov 26 04:41 PM
Autor Deborah M.	Director	Nov 22 '24	Sale	8.34	33,229	277,130	53,402	Nov 25 04:26 PM
Autor Deborah M.	Director	Nov 21 '24	Sale	8.41	6,771	56,944	86,631	Nov 25 04:26 PM
Daly Jason B.	SVP, Chief Legal Officer	Nov 21 '24	Sale	8.40	13,665	114,786	0	Nov 22 04:38 PM
Kiely John	Director	Nov 22 '24	Proposed Sale	8.33	17,058	142,175		Nov 22 10:39 AM
Autor Deborah M.	Director	Nov 21 '24	Proposed Sale	8.38	50,000	419,000		Nov 21 02:01 PM
Daly Jason B.	SVP, Chief Legal Officer	Nov 15 '24	Sale	8.61	43,657	375,887	13,665	Nov 19 04:17 PM
Daly Jason B.	Officer	Nov 15 '24	Proposed Sale	8.50	57,322	487,237		Nov 15 01:49 PM
BOYER ANDREW S	Executive Vice President	Aug 15 '24	Sale	7.85	40,225	315,766	256,670	Aug 16 04:18 PM
BOYER ANDREW S	Executive Vice President	Aug 14 '24	Sale	7.81	22,486	175,616	296,895	Aug 16 04:18 PM
Shah Nikita	Executive Vice President	Aug 14 '24	Sale	7.75	100,000	775,000	291,666	Aug 16 04:17 PM
BOYER ANDREW S	Officer	Aug 14 '24	Proposed Sale	7.80	70,000	546,000		Aug 14 03:56 PM
Shah Nikita	Officer	Aug 14 '24	Proposed Sale	7.86	70,000	550,200		Aug 14 03:12 PM
Shah Nikita	Officer	Aug 14 '24	Proposed Sale	7.86	30,000	235,800		Aug 14 11:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Amneal Pharmaceuticals Inc

Upgrade your FINVIZ experience